Coagulation factor II 280-760 IU + factor VII 180-480 IU + factor IX 500 IU + factor X 360-600 IU + protein C 260-620 IU + protein S 240-640 IU
Indications/Uses
Treatment & peri-op prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors when rapid deficiency correction is required & in congenital deficiency of vit K dependent coagulation factors when purified specific coagulation factor product is unavailable.
Discontinue use if allergic- or anaphylactic-type reactions occur. Patients w/ underlying hypercoaguable state; immunodeficiency or increased erythropoiesis eg, haemolytic anaemia; congenital or acquired deficiency; history of CHD; at risk of thromboembolic events or disseminated intravascular coagulation. Possibility of transmitting infective agents. Recommend appropriate vaccination (hepatitis A & B) for patients in regular/repeated receipt of human plasma-derived prothrombin complex products. Monitor for signs & symptoms of intravascular coagulation or thrombosis; peri- or post-op patients. Hepatic disease. Pregnancy & lactation. Neonates.
B02BD01 - coagulation factor IX, II, VII and X in combination ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.
Sign Out
